Morphic Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Morphic Therapeutic, a biopharmaceutical company focused on oral integrin therapies for chronic diseases, will participate in several investor conferences. CEO Praveen Tipirneni will join a fireside chat at the Wells Fargo Virtual Healthcare Conference on September 10 at 8:40 am ET. Additionally, the management team will hold virtual meetings during the Citi 15th Annual BioPharma Virtual Conference from September 8 to 11. A live webcast of the Wells Fargo session will be available on Morphic's website, along with an archived replay post-conference.

News Market Reaction – MORF

-0.60%

1 alert

-0.60% News Effect

On the day this news was published, MORF declined 0.60%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences:

• Praveen Tipirneni, M.D., president and chief executive officer is scheduled to take part in a fireside chat at 8:40 am ET on Thursday, September 10 at the 2020 Wells Fargo Virtual Healthcare Conference
• The Morphic management team will host virtual meetings during the Citi 15th Annual BioPharma Virtual Conference taking place from September 8 to 11

A live webcast of the Wells Fargo session will be available on the Investors section of Morphic’s website at https://www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts

Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

Media Contact
Tom Donovan, Ten Bridge Communications
tom@tenbridgecommunications.com
857.559.3397

 

FAQ

What will Morphic Therapeutic present at the Wells Fargo Virtual Healthcare Conference?

Morphic Therapeutic's CEO, Praveen Tipirneni, will participate in a fireside chat on September 10 at 8:40 am ET.

When is Morphic Therapeutic participating in the Citi 15th Annual BioPharma Virtual Conference?

Morphic Therapeutic will host virtual meetings during the Citi 15th Annual BioPharma Virtual Conference from September 8 to 11.

Where can I watch the webcast of Morphic Therapeutic's conference participation?

The live webcast of Morphic Therapeutic's session at the Wells Fargo conference will be available on their website.

What types of therapies is Morphic Therapeutic developing?

Morphic Therapeutic is developing oral integrin therapies for serious chronic diseases such as autoimmune diseases, cardiovascular and metabolic diseases, fibrosis, and cancer.

What is the ticker symbol for Morphic Therapeutic?

The ticker symbol for Morphic Therapeutic is MORF.